dendrimeraptam
conjug
polymeraptam
conjug
deliveri
aptam
cancer
aptam
rna
dna
oligonucleotid
interact
form
uniqu
target
conform
high
affin
specif
emerg
power
class
ligand
therapeut
applic
addit
dendrim
welldefin
nanos
symmetr
polymer
molecul
review
provid
analysi
use
dendrim
modifi
aptam
nonvir
vector
specif
target
tumor
cell
variou
anticanc
agent
encapsul
dendrim
complex
aptam
includ
epirubicin
camptothecin
bclxl
short
hairpin
sh
rna
rhodaminelabel
dextran
type
polymer
nanoparticl
np
aptam
bioconjug
also
develop
load
pt
iv
deriv
target
specif
tumor
cell
keyword
dendrim
space
aptam
polymer
nanoparticl
drug
deliveri
teaser
discuss
develop
dendrimerand
polymer
nanoparticleaptam
bioconjug
new
approach
medicin
aptamerbas
tool
therapeut
monitor
precis
therapi
aptam
come
latin
aptar
mean
fit
togeth
join
greek
mero
mean
part
nucleic
acid
aptam
short
chain
artifici
oligonucleotid
rna
singlestrand
dna
variabl
region
nucleotid
base
uniqu
flexibl
structur
high
affin
specif
ligandbind
capabl
strongli
relat
sequenc
import
characterist
increas
abil
differenti
target
contrast
antibodi
aptam
bind
function
domain
cognat
target
protein
eg
substrat
bind
pocket
alloster
site
figur
aptam
consid
smart
ligand
often
name
nucleic
acid
antibodi
bind
aptam
userdefin
target
occur
electrostat
interact
result
versatil
strong
bind
affin
except
specif
induc
nanoor
picomolar
dissoci
constant
kd
target
vari
small
ion
zn
larg
protein
coagul
factor
viii
whole
cell
virus
tissu
j
u
r
n
l
p
r
e
p
r
f
well
document
molecular
recognit
target
molecul
aptam
make
use
secondari
tertiari
structur
interact
small
molecul
eg
amino
acid
induc
structur
switch
chang
intern
loop
structur
aptam
compar
arrang
bind
larg
molecul
eg
enzym
regulatori
protein
growth
factor
monoclon
antibodi
import
advantag
aptam
tradit
antibodi
clinic
applic
includ
nonimmunogen
ii
high
celltissu
select
penetr
iii
numer
potenti
target
drug
discoveri
point
view
aptam
also
follow
advantag
tradit
antibodi
thermal
stabil
ii
less
batch
variabl
iii
short
product
time
iv
low
cost
importantli
larg
quantiti
aptam
obtain
use
biochem
synthesi
systemat
evolut
ligand
exponenti
enrich
selex
highthroughput
aptam
identif
screen
hapiscreen
nonequilibrium
capillari
electrophoresi
equilibrium
mixtur
neceem
one
area
interest
purifi
proteinbas
selex
select
aptam
recogn
cell
surfac
receptor
aptam
rapidli
elimin
bodi
renal
clearanc
short
halfliv
unmodifi
aptam
vivo
remain
one
major
challeng
develop
therapeut
aptam
inde
rnabas
aptam
prone
hydrolyt
breakdown
degrad
nucleas
avoid
degrad
sever
modif
rna
aptam
perform
improv
bioavail
pharmacokinet
paramet
pyrimidin
modif
ii
nucleotid
iii
cap
iv
introduct
cholesterol
polyethylen
glycol
peg
anchor
group
varieti
applic
aptam
also
develop
includ
new
drug
ii
therapeut
tool
iii
drug
deliveri
iv
diagnosi
diseas
base
aptamerbas
test
use
exampl
elisa
v
bioimag
vi
analyt
reagent
vii
food
inspect
viii
detect
use
optic
aptasensor
fluoresc
colorimetr
sensor
identif
quantif
environment
pollut
heavi
metal
ion
piezoelectr
massdepend
aptasensor
detect
virus
bacteria
toxin
electrochem
aptasensor
detect
lowmass
molecul
ion
thu
far
one
aptamerbas
drug
approv
us
food
drug
administr
fda
aptam
pegaptanib
aptam
strong
inhibit
angiogenesi
inhibit
extracellular
form
endotheli
growth
factor
use
treat
adult
wetform
agerel
macular
degener
develop
eyetechinpf
modifi
rna
deriv
pyrimidin
aptam
contain
purin
modif
enhanc
stabil
endonucleas
second
type
modif
perform
includ
introduct
moieti
attach
via
linkag
induc
good
pharmacokinet
profil
strong
protect
exonucleas
also
encapsul
poli
lacticcoglycol
acid
plga
microspher
transscler
deliveri
nanodevic
well
antivascular
endotheli
growth
factor
vegf
aptam
medic
applic
aptam
focu
rna
base
structur
divers
dnabas
aptam
exampl
cytoplasm
membran
tumor
cell
specif
aptam
interact
factor
intens
overexpress
surfac
tumor
cell
membran
use
vivo
molecular
imag
theranost
aptam
also
use
carrier
polymer
np
polylactid
conjug
antiprolif
drug
taxol
addit
aptam
deliv
cisplatin
aptamerfunction
pt
iv
prodrugplgapeg
np
prostat
tumor
cell
particular
interest
preclin
clinic
develop
aptam
thrombot
event
anticoagul
monitor
well
known
pegyl
polymer
np
significantli
reduc
system
clearanc
compar
similar
np
without
peg
chain
interestingli
aptam
use
specif
carrier
therapeut
oligonucleotid
small
interf
si
rna
mirna
shrna
antisens
oligonucleotid
aso
diagnosi
precis
medicin
person
medicin
exampl
cancer
treatment
main
aim
prepar
develop
chimera
aptam
one
part
aptam
target
purpos
link
second
part
therapeut
oligodeoxynucleotid
odn
transport
aptam
chemistri
dendrim
first
introduc
fritz
vogtl
cowork
well
tomalia
et
al
numer
biolog
studi
use
dendrim
carri
review
elsewher
dendrim
repres
uniqu
class
polym
highli
branch
architectur
shape
size
precis
control
size
one
import
paramet
evalu
strongli
influenc
clearanc
kinet
biodistribut
vivo
efficaci
np
nm
size
gener
induc
immun
respons
absorb
kupffer
cell
import
compon
mononuclear
phagocyt
system
contrast
smaller
np
nm
induc
rapid
clearanc
circul
np
nm
easili
clear
kidney
lymph
node
dendrim
display
exponenti
number
dendrit
branch
hydrophob
hydrophil
moieti
radiat
central
core
unit
figur
show
structur
unit
wellknown
poli
amidoamin
pamam
dendrim
core
surfac
group
void
space
interior
branch
interior
layer
gener
gn
n
gener
except
recent
even
compris
regularli
repeat
branch
unit
attach
core
shown
figur
dendrim
encapsul
biolog
activ
compound
yellow
ball
well
conjug
molecul
violet
ball
dendrim
also
use
drug
activ
per
se
dendrim
diamet
increas
linearli
wherea
number
surfac
group
molecular
weight
increas
exponenti
gener
figur
importantli
dendrim
collect
base
multipl
variat
chemic
structur
allow
monitor
chemic
properti
core
branch
surfac
group
introduct
vari
chemic
group
basic
acid
hydrophob
hydrogenbond
capabl
charg
etc
finetun
chemic
transform
allow
modif
composit
architectur
properti
dendrim
key
physicochem
properti
improv
vitro
vivo
behavior
interest
studi
taghdisi
et
al
involv
develop
aptamerbas
dendrim
doubl
target
strategi
two
aptam
encapsul
epirubicin
epi
anthracyclin
drug
act
cancer
cell
vitro
vivo
figur
clinic
administr
epi
eg
breast
colon
cancer
limit
nonspecif
interact
induc
cardiotox
bone
marrow
suppress
consequ
develop
new
nanosystem
avoid
advers
effect
need
new
strategi
base
preferenti
accumul
chemotherapeut
agent
cancer
site
consequ
decreas
advers
effect
aptam
select
bind
transmembran
glycosyl
glycoprotein
overexpress
mani
tumor
wherea
singlestrand
aptam
dna
aptam
sequenc
linkerggtggtggtggttgtggtggtggtgg
specif
bind
nucleu
membran
protein
nucleolin
overexpress
plasma
membran
tumor
cell
author
design
develop
origin
nanosystem
base
aptamerdendrim
conjug
gener
deliv
epi
breast
cancer
cell
murin
colon
carcinoma
cell
presenc
two
aptam
target
agent
dna
nanostructur
surfac
size
chemic
stabl
aptamerdendrim
nm
base
fluoresc
intens
gel
retard
assay
format
dendriplex
analyz
maximum
quench
ratio
dendrimerepi
correspond
mole
epi
load
mole
aptamerdendrim
releas
epi
aptamerdendrimerepi
complex
ph
depend
rapid
releas
epi
acid
ph
ph
cancer
tissu
lysosom
versu
physiolog
ph
epi
releas
ph
ph
h
probabl
proton
epi
lead
decreas
interact
epi
dendrim
nevertheless
process
uniqu
catalyt
enzym
lysosom
particip
disassembl
dendrim
induc
releas
epi
flow
cytometri
analysi
clearli
demonstr
dendriplex
specif
intern
tumor
cell
receptormedi
endocytosi
use
aptam
use
aptam
nonstandard
mechan
lead
accumul
complex
nucleu
intern
observ
nontarget
chines
hamster
ovari
cho
cell
intern
effect
also
valid
result
cell
viabil
assay
mtt
cho
cell
aptamerdendrimerepi
dendriplex
show
lower
toxic
cho
cell
versu
epi
alon
cell
viabil
respect
wherea
aptamerdendrimerepi
complex
cytotox
tumor
cell
compar
epi
alon
cell
viabil
respect
h
post
treatment
interestingli
aptamerdendrimerepi
dendriplex
show
better
vivo
antitumor
activ
mice
bear
cell
versu
epi
alon
similar
vivo
activ
compar
complex
data
confirm
aptamerdendrimerepi
dendriplex
modifi
two
type
aptam
differ
target
site
result
good
intern
target
cancer
cell
author
design
develop
pegyl
pamam
dendrim
load
camptothecin
cpt
topoisomeras
inhibitor
use
anticanc
agent
surfac
graft
antinucleolin
aptam
sitespecif
target
colorect
cancer
cell
overexpress
nucleolin
receptor
figur
one
problem
drug
deliveri
system
inabl
discrimin
target
cell
nontarget
cell
could
result
offtarget
deliveri
specif
drug
deliveri
approach
use
cell
surfac
receptor
overexpress
surfac
tumor
cell
bind
aptam
cell
surfac
receptor
intern
aptamerreceptor
complex
occur
via
receptormedi
endocyt
pathway
process
final
allow
deliveri
load
drug
target
deliveri
chemotherapeut
agent
instanc
could
increas
efficaci
reduc
offtarget
effect
effici
camptothecinencapsul
content
respect
vitro
releas
assay
camptothecin
demonstr
sustain
releas
anticanc
agent
day
phosphat
buffer
salin
pb
ph
citrat
buffer
ph
compar
pegpamamcpt
target
aptpegpamamcpt
formul
display
slower
cpt
releas
profil
decreas
diffus
rate
cpt
caviti
dendrim
dendrim
peripheri
modifi
aptam
biocompat
pegpamam
aptpegpamam
dendrim
versu
plain
pamam
dendrim
investig
via
hemolyt
assay
pamam
dendrim
show
signific
hemolyt
toxic
wherea
pegpamam
aptpegpamam
caus
lower
hemolyt
activ
mgml
concentr
two
nucleolinposit
cell
line
nucleolinneg
cell
line
cho
use
evalu
anticanc
activ
aptpegpamamcpt
pegpamamcpt
free
cpt
mtt
assay
show
aptpegpamamcpt
nanodevic
display
higher
antiprolifer
activ
toward
nucleolinposit
j
u
r
n
l
p
r
e
p
r
f
colorect
cancer
cell
compar
pegpamamcpt
aptpegpamamcpt
intern
bind
nucleolin
protein
cpt
pegpamamcpt
aptpegpamamcpt
cell
line
mgml
mgml
mgml
respect
wherea
cell
line
mgml
mgml
mgml
respect
improv
cellular
uptak
cell
aptpegpamamcpt
valid
use
fluoresc
microscopi
flow
cytometri
techniqu
vivo
studi
colorect
carcinoma
cell
line
subcutan
allograft
balbc
mice
show
aptpegpamamcpt
nanodevic
display
potent
antitumor
activ
improv
mous
surviv
rate
mgkg
iv
inject
twice
weekli
week
tumor
growth
inhibit
effect
pegpamamcpt
better
free
cpt
potent
effect
obtain
aptpegpamamcpt
enhanc
tumorinhibit
effect
aptpegpamamcpt
compar
pegpamamcpt
might
result
target
effect
conjug
aptam
bind
nucleolin
protein
cell
thu
possibl
delay
clearanc
tumor
site
author
also
report
deliveri
bclxl
shrna
pamam
dendrim
graft
aptam
target
ligand
figur
pamam
dendrim
modifi
acid
chain
ii
aptam
coval
noncoval
nucleolintarget
ligand
target
cancer
cell
overexpress
variou
cancer
cell
iii
shrna
plasmid
specif
knock
antiapoptot
bclxl
protein
express
nucleolinposit
cancer
cell
bclxl
express
sever
solid
tumor
neuron
tumor
adenocarcinoma
bladder
cancer
gastric
cancer
prepar
polyplex
show
typic
particl
size
nm
increas
dimens
aptam
conjug
charg
dendriplex
aptam
conjug
posit
mv
immunocytochemistri
analysi
show
presenc
nucleolin
receptor
surfac
cell
adenocarcinom
human
alveolar
basal
epitheli
cell
cell
neg
control
transfect
effici
complex
evalu
nucleolinexpress
cell
use
cell
neg
control
clearli
show
strong
transfect
efficaci
polyplex
bear
coval
noncoval
aptam
versu
nontarget
vector
cell
noncoval
conjug
also
exhibit
effici
compar
coval
bind
notabl
polyplex
prepar
show
viabil
without
aptam
base
western
blot
analys
express
level
bclxl
cell
express
reduc
polyplex
bear
shrna
versu
polyplex
bear
scrambl
shrna
complex
aptam
scrambl
shrna
significantli
chang
protein
express
level
result
show
high
silenc
bclxl
express
shrna
use
pamam
dendrim
bear
aptam
compar
pamam
dendrim
without
aptam
activ
polyplex
also
induc
apoptosi
target
cell
valid
flow
cytometr
analysi
work
team
concern
design
develop
function
pegyl
pamam
dendrim
conjug
aptam
encapsul
common
chemotherapeut
drug
figur
nanoparticl
name
increas
accumul
cancer
tumor
gastric
cancer
cell
effect
concentr
highest
encapsul
effici
observ
formul
ratio
atom
forc
microscopi
afm
topograph
imag
surfac
structur
confirm
chemic
structur
pamam
np
surfac
charg
zeta
potenti
dendriplex
mv
antiprolifer
assay
mtt
test
cell
dose
mgml
show
complex
display
percentag
viabil
cell
respect
cell
good
linear
also
observ
effect
dose
gml
dendriplex
cell
gml
gml
complex
cell
vivo
imag
studi
use
bodipi
fluoresc
dye
perform
mice
confirm
complex
intern
cell
result
specif
nucleolin
receptor
express
linkag
aptam
surfac
function
pamam
dendrim
increas
quantiti
conjug
bodipi
dye
complex
vicin
tumor
particular
interest
design
develop
polymer
npaptam
bioconjug
target
prostatespecif
membran
antigen
psma
overexpress
prostat
epitheli
cancer
cell
conjug
base
twopolym
system
poli
lactic
acid
blockpeg
copolym
termin
carboxyl
acid
function
group
plapegcooh
figur
np
encapsul
rhodaminelabel
dextran
model
drug
conjug
aptam
psam
target
agent
compound
link
end
aptam
analyz
specif
bind
membran
surfac
interact
use
light
transmiss
fluoresc
microscopi
techniqu
neg
surfacecharg
np
mv
minim
nonspecif
interact
neg
charg
nucleic
acid
rna
aptam
wherea
peg
chain
enhanc
circul
halflif
contribut
decreas
uptak
nontarget
cell
micronpaptam
bioconjug
show
narrow
size
distribut
pegyl
np
effici
target
prostat
lncap
psma
epitheli
cell
increas
bind
versu
psma
cell
control
importantli
np
target
cell
express
psa
occur
bind
np
lncap
epitheli
cell
easili
detect
earlystag
evalu
base
fluoresc
microscopi
imag
reconstruct
npaptam
bioconjug
strongli
intern
lncap
epitheli
cell
compar
cell
rhodaminedextran
encapsul
npaptam
bioconjug
team
develop
interest
construct
base
pt
iv
encapsul
psma
target
np
biodegrad
noncytotox
plgapegfunction
materi
construct
bear
aptamertarget
psma
psma
aptam
surfac
fitc
fluoresc
probe
polydispers
pt
iv
cargo
ptnpapt
increas
percentag
load
pt
iv
percentag
load
result
size
nm
nm
nm
nm
polydispers
index
respect
control
releas
kinet
pt
iv
complex
pb
ph
reach
h
h
target
uptak
ptnpapt
occur
via
endocytosi
psmaexpress
prostat
cancer
cell
lncap
psma
cell
receptormedi
endocytosi
induc
accumul
type
cell
accumul
pt
iv
complex
observ
psma
cell
total
pt
iv
releas
h
pb
medium
vitro
cellular
cytotox
assay
show
high
cytotox
ptnpapt
lncap
cell
versu
nontarget
nanoparticl
ptnp
cisplatin
ptnp
ptnpapt
wherea
cisplatin
show
use
gfp
monoclon
antibodi
use
detect
cisplatininduc
pt
adduct
dna
crosslink
pt
iv
dna
observ
lncap
cell
addit
exampl
describ
tong
et
al
use
sever
techniqu
concern
onestep
coprecipit
synthesi
develop
tunabl
polymer
np
base
aptamerco
paclitaxelpolylactid
la
nanoconjug
target
specif
tumor
cell
line
aptam
identifi
use
selex
techniqu
target
psma
vitro
vivo
fluoresc
dye
also
use
initi
la
polymer
result
np
coprecipit
polym
result
np
np
size
nm
polydispers
condens
aptam
carboxyl
function
result
size
nm
polydispers
confoc
imag
show
uptak
np
coat
aptam
significantli
enhanc
versu
uncoat
np
lncap
psma
assay
differ
coat
uncoat
nanoparticl
observ
cell
psma
bind
coat
np
higher
uncoat
np
lncap
cell
differ
observ
cell
compar
peptid
small
size
molecular
weight
major
advantag
use
polymeraptam
conjug
dendrimeraptam
conjug
increas
contact
area
ligand
target
receptor
enhanc
potenc
interact
target
receptor
increas
biostabl
exampl
nucleas
hydrolysi
human
serum
sever
strategi
develop
base
polymeraptam
conjug
conjug
ii
cholesterol
lipid
moieti
conjug
iii
pegyl
conjug
iv
modif
sugar
ring
aptam
v
replac
aptam
vi
modif
phosphodiest
linkag
base
aptam
vii
direct
conjug
aptam
np
gener
via
spacer
linker
maintain
aptamerbind
activ
exampl
approach
includ
antinucleolinspecif
dna
aptam
link
doxload
liposom
aptam
conjug
liposom
cisplatin
ii
aptam
function
surfac
np
iii
quantum
aptam
iv
thiolat
nucleic
acid
function
gold
np
aunp
appear
similar
morpholog
multival
polymeraptam
dendrimeraptam
conjug
although
research
requir
confirm
aptam
target
sever
acut
respiratori
syndrom
sar
coronaviru
helicas
also
report
characterist
featur
aptam
enabl
develop
mani
applic
instanc
antibodi
tradit
use
addit
aptam
use
biomark
discoveri
drug
discoveri
diagnost
therapeut
tradit
antibodi
special
deliveri
vehicl
dendrim
coat
specif
aptam
repres
novel
approach
tackl
tumor
cell
overexpress
correspond
antigen
prostat
lncap
psma
epitheli
cell
highlight
analyz
use
engin
dendrim
polym
nonvir
carrier
target
specif
tumor
base
bind
aptam
respect
biomark
surfac
tumor
cell
subsequ
control
releas
chemotherapeut
drug
howev
vivo
studi
perform
use
dendrimeraptam
bioconjug
thu
need
addit
vivo
studi
studi
requir
evalu
biodistribut
vehicl
system
administr
well
anticanc
properti
select
deliveri
therapeut
dose
drug
major
advantag
type
np
lastli
broadli
power
nanodrug
could
develop
specif
target
drug
deliveri
treat
myriad
diseas
